Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1038/s41467-017-00530-7

http://scihub22266oqcxt.onion/10.1038/s41467-017-00530-7
suck pdf from google scholar
28894087!5593860!28894087
unlimited free pdf from europmc28894087    free
PDF from PMC    free
html from PMC    free

Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=28894087&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215

suck abstract from ncbi

pmid28894087      Nat+Commun 2017 ; 8 (1): 517
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Hypoxia inducible factor HIF-1 promotes myeloid-derived suppressor cells accumulation through ENTPD2/CD39L1 in hepatocellular carcinoma #MMPMID28894087
  • Chiu DK; Tse AP; Xu IM; Di Cui J; Lai RK; Li LL; Koh HY; Tsang FH; Wei LL; Wong CM; Ng IO; Wong CC
  • Nat Commun 2017[Sep]; 8 (1): 517 PMID28894087show ga
  • Myeloid-derived suppressor cells (MDSCs) possess immunosuppressive activities, which allow cancers to escape immune surveillance and become non-responsive to immune checkpoints blockade. Here we report hypoxia as a cause of MDSC accumulation. Using hepatocellular carcinoma (HCC) as a cancer model, we show that hypoxia, through stabilization of hypoxia-inducible factor-1 (HIF-1), induces ectoenzyme, ectonucleoside triphosphate diphosphohydrolase 2 (ENTPD2/CD39L1), in cancer cells, causing its overexpression in HCC clinical specimens. Overexpression of ENTPD2 is found as a poor prognostic indicator for HCC. Mechanistically, we demonstrate that ENTPD2 converts extracellular ATP to 5'-AMP, which prevents the differentiation of MDSCs and therefore promotes the maintenance of MDSCs. We further find that ENTPD2 inhibition is able to mitigate cancer growth and enhance the efficiency and efficacy of immune checkpoint inhibitors. Our data suggest that ENTPD2 may be a good prognostic marker and therapeutic target for cancer patients, especially those receiving immune therapy.Myeloid-derived suppressor cells (MDSCs) promote tumor immune escape. Here, the authors show that in hepatocellular carcinoma, hypoxia induces the expression of ENTPD2 on cancer cells leading to elevated extracellular 5'-AMP, which in turn promote the maintenance of MDSCs by preventing their differentiation.
  • |Adenosine Triphosphatases/genetics/*metabolism[MESH]
  • |Carcinoma, Hepatocellular/*enzymology/genetics/metabolism/physiopathology[MESH]
  • |Cell Differentiation[MESH]
  • |Cell Proliferation[MESH]
  • |Humans[MESH]
  • |Hypoxia-Inducible Factor 1/genetics/*metabolism[MESH]
  • |Hypoxia/enzymology/genetics/metabolism/physiopathology[MESH]
  • |Liver Neoplasms/*enzymology/genetics/metabolism/physiopathology[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box